Small Cell Lung CancerPhase 3SKYSCRAPER-02NCT04256421
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
A Phase 3 study testing Tiragolumab, Atezolizumab and Carboplatin in people with Small Cell Lung Cancer, run by Hoffmann-La Roche at 121 sites in 23 countries.
Trial summary
This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Small Cell Lung Cancer
- What is being tested?
- Tiragolumab, Atezolizumab and Carboplatin
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 490 participants
- Where
- 121 sitesin 23 countries
- Study dates
- 4 Feb 2020to 31 Jul 2025
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC)
- No prior systemic treatment for ES-SCLC
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
- Adequate hematologic and end-organ function
- Treatment-free for at least 6 months since last chemo/radiotherapy, among those treated (with curative intent) with prior chemo/radiotherapy for limited-stage SCLC
Who cannot join
- Symptomatic or actively progressing central nervous system (CNS) metastases
- Malignancies other than small cell lung cancer (SCLC) within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Positive test result for human immunodeficiency virus (HIV)
- Active hepatitis B or hepatitis C
Show all 10Show fewer
- Severe infection at the time of randomization
- Treatment with any other investigational agent within 28 days prior to initiation of study treatment
- Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-cytotoxic T lymphocyte-associated protein 4 (anti-CTLA-4), anti-TIGIT, anti-PD-1, and anti-PD-L1 therapeutic antibodies
- Treatment with systemic immunostimulatory agents within 4 weeks or 5 drug elimination half-lives prior to randomization
Trial locations and contacts
121 sites in 23 countries.
121 sites in 23 countries
United States18 sites
Texas Oncology Cancer Center
Austin, Texas, 78731
Weinberg Cancer Institution at Franklin Square
Baltimore, Maryland, 21237
Broome Oncology - Binghamton
Binghamton, New York, 13905
Sarah Cannon Research Institute / Tennessee Oncology
Chattanooga, Tennessee, 37404
Virginia Cancer Specialists
Fairfax, Virginia, 22031
Florida Cancer Specialists
Fort Myers, Florida, 33901
Comprehensive Cancer Centers of Nevada
Henderson, Nevada, 89052
Rocky Mountain Cancer Centers - Lone Tree
Lone Tree, Colorado, 80124
University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, 53792
Northwest Georgia Oncology Centers PC - Marietta
Marietta, Georgia, 30060
Minnesota Oncology Hematology
Minneapolis, Minnesota, 55404
Sarah Cannon Research Inst.
Nashville, Tennessee, 37203
Memorial Sloan Kettering Cancer Center
New York, New York, 10065
Illinois Cancer Care
Peoria, Illinois, 61615
Blue Ridge Cancer Care
Roanoke, Virginia, 24014
SCRI Florida Cancer Specialists North
Sarasota, Florida, 34232
New England Cancer Specialists
Scarborough, Maine, 04074
MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center)
Washington D.C., District of Columbia, 20007
Japan11 sites
National Cancer Center Hospital East
Chiba, 277-8577
Kyushu University Hospital
Fukuoka, 812-8582
Niigata Cancer Center Hospital
Niigata, 951-8566
Osaka International Cancer Institute
Osaka, 541-8567
Kindai University Hospital
Osaka, 589-8511
NHO Kinki-Chuo Chest Medical Center
Osaka, 591-8555
Saitama Cancer Center
Saitama, 362-0806
Shizuoka Cancer Center
Shizuoka, 411-8777
National Cancer Center Hospital
Tokyo, 104-0045
The Cancer Institute Hospital of JFCR
Tokyo, 135-8550
Wakayama Medical University Hospital
Wakayama, 641-8510
South Korea10 sites
Chungbuk National University Hospital
Cheongju-si, 28644
National Cancer Center
Gyeonggi-do, 10408
Seoul National University Bundang Hospital
Gyeonggi-do, 13620
Samsung Changwon Hospital
Gyeongsangnam-do, 51353
Seoul National University Hospital
Seoul, 03080
Severance Hospital, Yonsei University Health System
Seoul, 03722
Asan Medical Center
Seoul, 05505
Samsung Medical Center
Seoul, 06351
Seoul St Mary's Hospital
Seoul, 06591
Ulsan University Hosiptal
Ulsan, 44033
Spain8 sites
Vall d?Hebron Institute of Oncology (VHIO), Barcelona
Barcelona, 08035
Hospital Clinic Barcelona
Barcelona, 08036
Fundacion Jimenez Diaz
Madrid, 28040
Hospital Universitario La Paz
Madrid, 28046
Hospital Clinico Universitario Virgen de la Victoria
Málaga, 29010
Hospital Universitario Virgen del Rocio
Seville, 41013
Hospital Clínico Universitario de Valencia
Valencia, 46010
Hospital Clinico Universitario Lozano Blesa
Zaragoza, 50009
Italy7 sites
Irccs Ist. Tumori Giovanni Paolo Ii
Bari, Apulia, 70124
Azienda Ospedaliero-Universitaria ?PoliclinicoVittorio Emanuele?- P.O. G. Rodolico
Catania, Sicily, 95123
AORN Ospedali dei Colli Ospedale Monaldi
Naples, Campania, 80131
Azienda Sanitaria Ospedaliera S Luigi Gonzaga
Orbassano, Piedmont, 10043
IRCCS Istituto Oncologico Veneto (IOV)
Padova, Veneto, 35128
AUSL della Romagna
Ravenna, Emilia-Romagna, 48121
IRCCS Istituto Clinico Humanitas
Rozzano, Lombardy, 20089
Poland7 sites
Szpital Specjalistyczny Podkarpacki O?rodek Onkologiczny
Brzozów, 36-200
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii
Gdansk, 80-214
Krakowski Szpital Specjalistyczny im sw.Jana Pawla II
Krakow, 31-202
Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
Olsztyn, 10-357
Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy
Otwock, 05-400
Wielkopolskie Centrum Pulmonologii i Torakochirurgii w Poznaniu
Poznan, 60-569
Narod.Inst.Onkol. im. M.Sklodowskiej - Curie-Panst.Inst.Bad
Warsaw, 02-781
Brazil6 sites
Clínica de Oncologia Reichow
Blumenau, Santa Catarina, 89010-340
Oncocentro Serviços Médicos e Hospitalares Ltda
Fortaleza, Ceará, 60130-241
Hospital de Clínicas de Passo Fundo
Passo Fundo, Rio Grande do Sul, 99010-260
Hospital Nossa Senhora da Conceicao
Porto Alegre, Rio Grande do Sul, 91350-200
Hospital Sao Rafael - HSR
Salvador, Estado de Bahia, 41253-190
Instituto do Cancer do Estado de Sao Paulo - ICESP
São Paulo, São Paulo, 01246-000
Germany6 sites
Helios Klinikum Emil von Behring GmbH
Berlin, 14165
LungenClinic Großhansdorf GmbH
Großhansdorf, 22927
Asklepios Klinik Harburg
Hamburg, 21075
Fachklinik für Lungenerkrankungen
Immenhausen, 34376
Universitätsklinikum Schleswig-Holstein
Lübeck, 23538
Asklepios Klinik Gauting
München-Gauting, 82131
Turkey (Türkiye)6 sites
Adana Baskent University Hospital
Adana, 01120
Ankara University Medical Faculty
Ankara, 06100
Gazi University Medical Faculty
Ankara, 06500
Istanbul University Cerrahpa?a-Cerrahpa?a Medical Faculty
Istanbul, 34098
Medipol University Medical Faculty
Istanbul, 34214
?zmir Medical Park
Izm?r, 35575
Australia4 sites
Sunshine Coast University Hospital
Birtinya, Queensland, 4575
Chris O'Brien Lifehouse
Camperdown, New South Wales, 2050
Lyell McEwin Hospital
Elizabeth Vale, South Australia, 5112
Nepean Hospital
Kingswood, New South Wales, 2747
Belgium4 sites
AZ St Maarten Campus Leopoldstr
Mechelen, 2800
Clinique Ste-Elisabeth
Namur, 5000
AZ Delta (Campus Rumbeke)
Roeselare, 8800
Vitaz
Sint-Niklaas, 9100
Greece4 sites
General Hospital "G.Papanikolaou"
Asvestochóri, 570 10
Uoa Sotiria Hospital
Athens, 115 27
Metropolitan General Hospital
Cholargós, 155 62
Univ General Hosp Heraklion
Heraklion, 711 10
Taiwan4 sites
National Cheng-Kung University Hospital
Tainan, 70401
Taipei Veterans General Hospital
Taipei, 11217
Chang-Gung Medical Foundation, Linkou Branch
Taoyuan, 333
National Taiwan University Hospital
Zhongzheng Dist., 10048
United Kingdom4 sites
NHS Lothian - Western General Hospital
Edinburgh, EH4 2XU
Guys and St Thomas Hospital
London, SE1 9RT
Christie Foundation Trust
Manchester, M20 4BX
Royal Cornwall Hospital
Truro, TR1 3LQ
Austria3 sites
Tiroler Landeskrankenanstalten Ges.M.B.H.
Innsbruck, 6020
Klinik Penzing
Vienna, 1140
Krankenhaus Nord - Klinik Floridsdorf
Vienna, 1210
Czechia3 sites
Fakultni nemocnice Olomouc
Olomouc, 775 20
Vitkovicka Nemocnice Bma, A.S.
Ostrava, 703 84
Thomayerova nemocnice
Praha 4 - Krc, 140 59
Hungary3 sites
Orszagos Koranyi TBC es Pulmonologiai Intezet
Budapest, 1121
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rend.Int.
Szolnok, 5000
Tudogyogyintezet Torokbalint
Törökbálint, 2045
Russia3 sites
Principal Military Clinical Hospital n.a. N.N. Burdenko
Moscow, Moscow Oblast, 105229
Blokhin Cancer Research Center
Moscow, Moscow Oblast
Scientific Research Institute n.a. N.N. Petrov
Saint Petersburg, Sankt-Peterburg, 187758
Serbia3 sites
Clinical Center of Serbia
Belgrade, 11000
Clinical Hospital Center ''Bezanijska Kosa''
Belgrade, 11080
Institute for Pulmonary Diseases of Vojvodina
Kamenitz, 21204
Netherlands2 sites
Maastricht University Medical Center
Maastricht, 6229 HX
Erasmus MC
Rotterdam, 3015 GD
Singapore2 sites
National University Hospital
Singapore, 119228
National Cancer Centre
Singapore, 168583
Switzerland2 sites
CHUV
Lausanne, 1011
UniversitätsSpital Zürich
Zurich, 8091
About this study
Official title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be stratified by Eastern Cooperative Oncology Group (ECOG) Performance Status (0 vs. 1), LDH (</= upper limit of normal [ULN] vs. > ULN), and presence or history of brain metastasis (yes vs. no) and randomly assigned in a 1:1 ratio to receive one of the following treatment regimens during induction phase:
- Arm A: Tiragolumab plus atezolizumab plus CE
- Arm B: Placebo plus atezolizumab plus CE
Following the induction phase, participants will continue maintenance therapy with either atezolizumab plus tiragolumab (Arm A) or atezolizumab plus placebo (Arm B).
- Conditions
- Small Cell Lung Cancer
- Being tested
- Tiragolumab, Atezolizumab, Carboplatin, Etoposide, Placebo
- Medical subject headings
- Small Cell Lung Carcinoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TiragolumabDrug
Also called MTIG7192A
Tiragolumab 600 milligrams (mg) administered by IV infusion on Day 1 of each 21-day cycle.
AtezolizumabDrug
Also called Tecentriq
Atezolizumab 1200 mg administered by IV infusion on Day 1 of each 21-day cycle.
CarboplatinDrug
Carboplatin was administered by IV infusion on Day 1 of each 21-day cycle for 4 cycles.
EtoposideDrug
Etoposide 100 mg/m^2 administered by IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles.
PlaceboDrug
Placebo administered by IV infusion on Day 1 of each 21-day cycle.
| Study group | Role | What they receive |
|---|---|---|
| Placebo + Atezolizumab + CE | Active comparator | Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by placebo on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3. Receives: Drug: Atezolizumab; Drug: Carboplatin; Drug: Etoposide; Drug: Placebo |
| Tiragolumab + Atezolizumab + CE | Experimental | Participants will receive atezolizumab on Day 1 of each 21-day cycle followed by tiragolumab on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3. Receives: Drug: Tiragolumab; Drug: Atezolizumab; Drug: Carboplatin; Drug: Etoposide |
What is being measured
The primary outcome is the main question the study is designed to answer.
Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS)
PFS was defined as the time from randomization to the first documented PD as determined by the investigator with the use of Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm).
Measured: From randomization to the first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24 months)
Overall Survival (OS) in the PAS
OS was defined as the time from randomization to death from any cause.
Measured: From randomization to death from any cause (up to approximately 24 months)
Secondary outcomes (22)
PFS in the FAS
PFS was defined as the time from randomization to the first documented PD as determined by the investigator with the use of RECIST v1.1 or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm.
Measured: From randomization to the first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24 months)
OS in the FAS
OS was defined as the time from randomization to death from any cause.
Measured: From randomization to death from any cause (up to approximately 24 months)
Investigator-assessed Confirmed Objective Response Rate (ORR) in the PAS
ORR was defined as the percentage of participants with a complete response (CR) or a partial response (PR) as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.
Measured: From randomization up to approximately 24 months
Investigator-assessed Confirmed ORR in the FAS
ORR was defined as the percentage of participants with CR or PR as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. Percentages have been rounded off.
Measured: From randomization up to approximately 24 months
Investigator-assessed Duration of Response (DOR) in the PAS
DOR was defined as the time from the first occurrence of a documented OR (CR or PR) to PD or death from any cause, whichever occurred first, as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm.
Measured: From the first occurrence of a documented confirmed objective response (OR) to PD or death from any cause, whichever occurred first (up to approximately 24 months)
Investigator-assessed DOR in the FAS
DOR was defined as the time from the first occurrence of a documented OR (CR or PR) to PD or death from any cause, whichever occurred first, as determined by the investigator with the use of RECIST v1.1. CR was defined as disappearance of all target lesions or any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. PR was defined as at least a 30% decrease in the SOD of all target lesions, taking as reference the baseline SOD, in the absence of CR. PD was defined as at least a 20% increase in the SOD of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 mm.
Measured: From the first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 24 months)
Investigator-assessed PFS Rates at 6 Months and 12 Months in the PAS
PFS rate at 6 months and 12 months was defined as the percentage of participants who were event-free at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate was a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value was calculated from ordered data (Event, Censoring) of each participant, using the Kaplan-Meier (K-M) method, accounting for censored observations (so event-free rates may not directly be calculated based only on participants remaining at risk).
Measured: Month 6, Month 12
Investigator-assessed PFS Rates at 6 Months and 12 Months in the FAS
PFS rate at 6 months and 12 months was defined as the percentage of participants who were event-free at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate was a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value was calculated from ordered data (Event, Censoring) of each participant, using the K-M method, accounting for censored observations (so event-free rates may not directly be calculated based only on participants remaining at risk).
Measured: Month 6, Month 12
OS Rates at 12 Months and 24 Months in the PAS
OS rate at 12 months and 24 months was defined as the percentage of participants who were alive at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate was a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value was calculated from ordered data (Event, Censoring) of each participant, using the K-M method, accounting for censored observations (so event-free rates may not directly be calculated based only on participants remaining at risk).
Measured: Month 12, Month 24
OS Rates at 12 Months and 24 Months in the FAS
OS rate at 12 months and 24 months was defined as the percentage of participants who were alive at these specific time points. Percentages have been rounded off to the nearest decimal point. A point estimate of the event-free rate was a single, numerical value used to approximate the true event-free rate of the entire population at a specific point in time. This value was calculated from ordered data (Event, Censoring) of each participant, using the K-M method, accounting for censored observations (so event-free rates may not directly be calculated based only on participants remaining at risk).
Measured: Month 12, Month 24
Time to Confirmed Deterioration (TTCD) of European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-life Questionnaire-Core 30 (QLQ-C30) Physical Functioning (PF) in the PAS
TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in PF. TTCD was determined based on patient-reported PF (Items 1-5) as collected and measured by the EORTC QLQ-C30. The PF was measured on 4-point scale (1='Not at all' to 4='Very much'). A high score for the PF subscale represented a high/healthy level of functioning. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in PF subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.
Measured: From randomization until the first confirmed clinically meaningful deterioration (up to approximately 24 months)
TTCD of EORTC QLQ-C30 Physical Functioning in the FAS
TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in PF. TTCD was determined based on patient-reported PF (Items 1-5) as collected and measured by the EORTC QLQ-C30. The PF was measured on 4-point scale (1='Not at all' to 4='Very much'). A high score for the PF subscale represented a high/healthy level of functioning. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in PF subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.
Measured: From randomization until the first confirmed clinically meaningful deterioration (up to approximately 24 months)
TTCD of EORTC QLQ-C30 Global Health Status (GHS)/Quality-of-life (QoL) in the PAS
TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in patient-reported GHS/QoL. TTCD was determined based on patient-reported GHS/QoL (Items 29-30) as collected and measured by the EORTC QLQ-C30. GHS/QoL items were scored on a 7-point scale, ranging from "very poor" to "excellent". A high score for the GHS/QoL subscale represented a high health-related QoL. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in GHS/QoL subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.
Measured: From randomization until the first confirmed clinically meaningful deterioration (up to approximately 24 months)
TTCD of EORTC QLQ-C30 GHS/QoL in the FAS
TTCD was the time from randomization until the first confirmed clinically meaningful deterioration in patient-reported GHS/QoL. TTCD was determined based on patient-reported GHS/QoL (Items 29-30) as collected and measured by the EORTC QLQ-C30. GHS/QoL items were scored on a 7-point scale, ranging from "very poor" to "excellent". A high score for the GHS/QoL subscale represented a high health-related QoL. The scale was linearly transformed so that each score ranged from 0 to 100. A score change of at least 10-point in GHS/QoL subscale score was perceived by participants as clinically meaningful. Confirmed clinically meaningful deterioration was defined as a clinically meaningful decrease from baseline that was held for at least two consecutive assessments or an initial clinically meaningful decrease from baseline followed by death from any cause within 3 weeks.
Measured: From randomization until the first confirmed clinically meaningful deterioration (up to approximately 24 months)
Number of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsen during a study were also considered as AEs.
Measured: Up to 58 months
Number of Participants With Severity of Cytokine-release Syndrome (CRS), as Determined by the American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale
CRS=supraphysiologic response following administration of any immune therapy that results in activation/engagement of endogenous or infused T cells and/or other immune effector cells. Symptoms may be progressive, including fever at onset, and may also include hypotension, capillary leak (hypoxia), and end-organ dysfunction. Severity of CRS was determined per ASTCT Consensus Grading Criteria, which categorizes CRS into 5 grades: Grade 1: Fever (≥38◦Celsius), with/without constitutional symptoms, in absence of hypotension \& hypoxia; Grade 2: Fever with hypotension not requiring vasopressors and/or hypoxia requiring low-flow oxygen; Grade 3: Fever with hypotension requiring one vasopressor, with/without vasopressin, and/or hypoxia requiring high-flow oxygen; Grade 4: Fever accompanied by hypotension requiring multiple vasopressors (excluding vasopressin) and/or hypoxia requiring positive-pressure ventilation; Grade 5: death due to CRS. Only non zero values have been reported.
Measured: Up to 58 months
Minimum Serum Concentration (Cmin) of Tiragolumab
Measured: At the end of Cycles 1, 2, 3, 7, 11 and 15 (approximately 11 months) (1 Cycle=21 days)
Cmin of Atezolizumab
Measured: At the end of each Cycles 1, 2, 3, 7, 11 and 15 (approximately 11 months) (1 Cycle=21 days)
Maximum Serum Concentration (Cmax) of Tiragolumab
Measured: Pre-dose and 30 minutes post end of infusion (EOI) on Day 1 of Cycle 1 (1 Cycle=21 days)
Cmax of Atezolizumab
Measured: Pre-dose and 30 minutes post EOI on Day 1 of Cycle 1 (1 Cycle=21 days)
Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab
Participants were considered to be ADA-positive if they were ADA-negative at baseline but developed an ADA response following tiragolumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such at least 0.60 titer unit (t.u.) greater than the baseline titer result (treatment-enhanced ADA response). The total number of participants who developed ADAs to tiragolumab was determined by summing the ADA-positive participants across all timepoints.
Measured: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8,12, 16 and at treatment discontinuation (TD) visit (up to 24 months) (1 Cycle=21 days)
Number of Participants With ADAs to Atezolizumab
Participants were considered to be ADA-positive if they were ADA-negative at baseline but developed an ADA response following atezolizumab administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such at least 0.60 t.u. greater than the baseline titer result (treatment-enhanced ADA response). The total number of participants who developed ADAs to tiragolumab was determined by summing the ADA-positive participants across all timepoints.
Measured: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8,12, 16 and at TD visit (up to 24 months) (1 Cycle=21 days)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Feb 2020
- Study start4 Feb 2020
- Primary completion6 Sep 2022
- Study completion31 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Small Cell Lung CancerStudies of the same condition, open and under way.
- More trials run by Hoffmann-La RocheThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 490 participants (actual)
Sponsor and investigators
- Lead sponsor
- Hoffmann-La Roche
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Clinical Trials, Study director, Hoffmann-La Roche
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04256421
- Sponsor's protocol ID
- GO41767
- Other IDs
- 2019-003301-97, 2019
- Acronym
- SKYSCRAPER-02
- Status last verified
- Mar 2026
- First submitted
- 31 Jan 2020
- Last updated
- 3 Apr 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data\_sharing
Publications
Rudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee JS, Bryl M, Dumoulin DW, Rittmeyer A, Chiu CH, Ozyilkan O, Johnson M, Navarro A, Novello S, Ozawa Y, Tam SH, Patil NS, Wen X, Huang M, Hoang T, Meng R, Reck M. SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2024 Jan 20;42(3):324-335. doi: 10.1200/JCO.23.01363. Epub 2023 Nov 17.
PubMed 37976444
Study at a glance
From the registry record, last updated by the sponsor on 3 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab (Anti-Tigit Antibody) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
- ClinicalTrials.gov ID
- NCT04256421
- Acronym / sponsor ID
- SKYSCRAPER-02 / GO41767
- Conditions
- Small Cell Lung Cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 490 participants (actual)
- Lead sponsor
- Hoffmann-La RocheIndustry (pharma, biotech, devices)
- Study start
- 4 Feb 2020 (actual)
- Primary completion
- 6 Sep 2022 (actual)
- Study completion
- 31 Jul 2025 (actual)
- First posted
- 5 Feb 2020 (actual)
- Results
- Posted 22 Oct 2025
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with chemotherapy-naive extensive-stage small cell lung cancer (ES-SCLC). Eligible participants will be stratified by Eastern Cooperative Oncology Group (ECOG) Performance Status (0 vs. 1), LDH (</= upper limit of normal [ULN] vs. > ULN), and presence or history of brain metastasis (yes vs. no) and randomly assigned in a 1:1 ratio to receive one of the following treatment regimens during induction phase:
- Arm A: Tiragolumab plus atezolizumab plus CE
- Arm B: Placebo plus atezolizumab plus CE
Following the induction phase, participants will continue maintenance therapy with either atezolizumab plus tiragolumab (Arm A) or atezolizumab plus placebo (Arm B).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Placebo + Atezolizumab + CE | Active comparator | Drug: Atezolizumab, Drug: Carboplatin, Drug: Etoposide, Drug: PlaceboParticipants will receive atezolizumab on Day 1 of each 21-day cycle followed by placebo on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3. |
| Tiragolumab + Atezolizumab + CE | Experimental | Drug: Tiragolumab, Drug: Atezolizumab, Drug: Carboplatin, Drug: EtoposideParticipants will receive atezolizumab on Day 1 of each 21-day cycle followed by tiragolumab on Day 1 of each 21-day cycle. Carboplatin will be administered followed by etoposide on Day 1 for 4 cycles. Participants will also receive etoposide on Days 2 and 3. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC)
- No prior systemic treatment for ES-SCLC
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
- Adequate hematologic and end-organ function
Key exclusion criteria (10 listed)
- Symptomatic or actively progressing central nervous system (CNS) metastases
- Malignancies other than small cell lung cancer (SCLC) within 5 years prior to randomization, with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
- Positive test result for human immunodeficiency virus (HIV)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TiragolumabAlso: MTIG7192ATiragolumab 600 milligrams (mg) administered by IV infusion on Day 1 of each 21-day cycle. | Drug | Tiragolumab + Atezolizumab + CE |
| AtezolizumabAlso: TecentriqAtezolizumab 1200 mg administered by IV infusion on Day 1 of each 21-day cycle. | Drug | Placebo + Atezolizumab + CE, Tiragolumab + Atezolizumab + CE |
| CarboplatinCarboplatin was administered by IV infusion on Day 1 of each 21-day cycle for 4 cycles. | Drug | Placebo + Atezolizumab + CE, Tiragolumab + Atezolizumab + CE |
| EtoposideEtoposide 100 mg/m^2 administered by IV infusion on Days 1, 2 and 3 of each 21-day cycle for 4 cycles. | Drug | Placebo + Atezolizumab + CE, Tiragolumab + Atezolizumab + CE |
| PlaceboPlacebo administered by IV infusion on Day 1 of each 21-day cycle. | Drug | Placebo + Atezolizumab + CE |
Primary outcome
Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS)
Time frame: From randomization to the first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24 months)
PFS was defined as the time from randomization to the first documented PD as determined by the investigator with the use of Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions, taking as reference the smallest SOD on study (including baseline). In addition to the relative increase of 20%, the SOD must also demonstrate an absolute increase of ≥ 5 millimeters (mm).
Overall Survival (OS) in the PAS
Time frame: From randomization to death from any cause (up to approximately 24 months)
OS was defined as the time from randomization to death from any cause.
22 secondary outcomes
PFS in the FAS
Time frame: From randomization to the first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24 months)
OS in the FAS
Time frame: From randomization to death from any cause (up to approximately 24 months)
Investigator-assessed Confirmed Objective Response Rate (ORR) in the PAS
Time frame: From randomization up to approximately 24 months
Investigator-assessed Confirmed ORR in the FAS
Time frame: From randomization up to approximately 24 months
Investigator-assessed Duration of Response (DOR) in the PAS
Time frame: From the first occurrence of a documented confirmed objective response (OR) to PD or death from any cause, whichever occurred first (up to approximately 24 months)
Investigator-assessed DOR in the FAS
Time frame: From the first occurrence of a documented confirmed OR to PD or death from any cause, whichever occurred first (up to approximately 24 months)
Investigator-assessed PFS Rates at 6 Months and 12 Months in the PAS
Time frame: Month 6, Month 12
Investigator-assessed PFS Rates at 6 Months and 12 Months in the FAS
Time frame: Month 6, Month 12
OS Rates at 12 Months and 24 Months in the PAS
Time frame: Month 12, Month 24
OS Rates at 12 Months and 24 Months in the FAS
Time frame: Month 12, Month 24
Time to Confirmed Deterioration (TTCD) of European Organisation for Research and Treatment of Cancer (EORTC) Quality-of-life Questionnaire-Core 30 (QLQ-C30) Physical Functioning (PF) in the PAS
Time frame: From randomization until the first confirmed clinically meaningful deterioration (up to approximately 24 months)
TTCD of EORTC QLQ-C30 Physical Functioning in the FAS
Time frame: From randomization until the first confirmed clinically meaningful deterioration (up to approximately 24 months)
TTCD of EORTC QLQ-C30 Global Health Status (GHS)/Quality-of-life (QoL) in the PAS
Time frame: From randomization until the first confirmed clinically meaningful deterioration (up to approximately 24 months)
TTCD of EORTC QLQ-C30 GHS/QoL in the FAS
Time frame: From randomization until the first confirmed clinically meaningful deterioration (up to approximately 24 months)
Number of Participants With Adverse Events (AEs)
Time frame: Up to 58 months
Number of Participants With Severity of Cytokine-release Syndrome (CRS), as Determined by the American Society for Transplantation and Cell Therapy (ASTCT) Consensus Grading Scale
Time frame: Up to 58 months
Minimum Serum Concentration (Cmin) of Tiragolumab
Time frame: At the end of Cycles 1, 2, 3, 7, 11 and 15 (approximately 11 months) (1 Cycle=21 days)
Cmin of Atezolizumab
Time frame: At the end of each Cycles 1, 2, 3, 7, 11 and 15 (approximately 11 months) (1 Cycle=21 days)
Maximum Serum Concentration (Cmax) of Tiragolumab
Time frame: Pre-dose and 30 minutes post end of infusion (EOI) on Day 1 of Cycle 1 (1 Cycle=21 days)
Cmax of Atezolizumab
Time frame: Pre-dose and 30 minutes post EOI on Day 1 of Cycle 1 (1 Cycle=21 days)
Number of Participants With Anti-drug Antibodies (ADAs) to Tiragolumab
Time frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8,12, 16 and at treatment discontinuation (TD) visit (up to 24 months) (1 Cycle=21 days)
Number of Participants With ADAs to Atezolizumab
Time frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 4, 8,12, 16 and at TD visit (up to 24 months) (1 Cycle=21 days)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Apr 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 37976444Rudin CM, Liu SV, Soo RA, Lu S, Hong MH, Lee JS, Bryl M, Dumoulin DW, Rittmeyer A, Chiu CH, Ozyilkan O, Johnson M, Navarro A, Novello S, Ozawa Y, Tam SH, Patil NS, Wen X, Huang M, Hoang T, Meng R, Reck M. SKYSCRAPER-02: Tiragolumab in Combination With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage Small-Cell Lung Cancer. J Clin Oncol. 2024 Jan 20;42(3):324-335. doi: 10.1200/JCO.23.01363. Epub 2023 Nov 17.
- Individual participant dataSharing planned: Yes. For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Related trials for Small Cell Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
RecruitingPhase 2
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Carcinoma, Neuroendocrine, Tumor, Neuroendocrine
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Clinical Trials study director
Hoffmann-La Roche
121 sites in 23 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Tiragolumab, Atezolizumab and Carboplatin in people with Small Cell Lung Cancer, run by Hoffmann-La Roche at 121 sites in 23 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 3 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 121 sites in United States, Japan, South Korea, Spain, Italy and 18 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Oct 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Investigator-assessed Progression-free Survival (PFS) in the Primary Analysis Set (PAS) (time frame: From randomization to the first occurrence of PD or death from any cause, whichever occurred first (up to approximately 24 months)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04256421, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2026.